JP2022547335A - 組換えヒトニューレグリン誘導体及びその使用 - Google Patents

組換えヒトニューレグリン誘導体及びその使用 Download PDF

Info

Publication number
JP2022547335A
JP2022547335A JP2022516691A JP2022516691A JP2022547335A JP 2022547335 A JP2022547335 A JP 2022547335A JP 2022516691 A JP2022516691 A JP 2022516691A JP 2022516691 A JP2022516691 A JP 2022516691A JP 2022547335 A JP2022547335 A JP 2022547335A
Authority
JP
Japan
Prior art keywords
nrg
amino acid
acid sequence
fusion polypeptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547335A5 (enExample
Inventor
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010955006.XA external-priority patent/CN112500493A/zh
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2022547335A publication Critical patent/JP2022547335A/ja
Publication of JP2022547335A5 publication Critical patent/JP2022547335A5/ja
Priority to JP2025136792A priority Critical patent/JP2025186253A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022516691A 2019-09-16 2020-09-14 組換えヒトニューレグリン誘導体及びその使用 Pending JP2022547335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136792A JP2025186253A (ja) 2019-09-16 2025-08-20 組換えヒトニューレグリン誘導体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910873003 2019-09-16
CN201910873003.9 2019-09-16
CN202010955006.X 2020-09-11
CN202010955006.XA CN112500493A (zh) 2019-09-16 2020-09-11 重组人神经调节蛋白衍生物及其用途
PCT/CN2020/114955 WO2021052277A1 (zh) 2019-09-16 2020-09-14 重组人神经调节蛋白衍生物及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136792A Division JP2025186253A (ja) 2019-09-16 2025-08-20 組換えヒトニューレグリン誘導体及びその使用

Publications (2)

Publication Number Publication Date
JP2022547335A true JP2022547335A (ja) 2022-11-11
JP2022547335A5 JP2022547335A5 (enExample) 2023-09-15

Family

ID=74883174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516691A Pending JP2022547335A (ja) 2019-09-16 2020-09-14 組換えヒトニューレグリン誘導体及びその使用
JP2025136792A Pending JP2025186253A (ja) 2019-09-16 2025-08-20 組換えヒトニューレグリン誘導体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136792A Pending JP2025186253A (ja) 2019-09-16 2025-08-20 組換えヒトニューレグリン誘導体及びその使用

Country Status (7)

Country Link
US (1) US20230057622A1 (enExample)
EP (1) EP4032901A4 (enExample)
JP (2) JP2022547335A (enExample)
KR (1) KR20220066116A (enExample)
AU (1) AU2020348436A1 (enExample)
CA (1) CA3157354A1 (enExample)
WO (1) WO2021052277A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160165860A1 (en) * 2013-07-24 2016-06-16 The University Court of the University of Edinburg h Domain 5 of CD163 for Use in Antiviral Compositions Against PRRS, and Transgenic Animals
JP2017502969A (ja) * 2014-01-03 2017-01-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリン調合剤の処方
WO2018167320A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2019143272A1 (en) * 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN105497876B (zh) * 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN108623672A (zh) * 2017-03-25 2018-10-09 成都贝爱特生物科技有限公司 新的egf-a和b的组合突变体制备及其在生物药物中的应用
FI3774859T3 (fi) * 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160165860A1 (en) * 2013-07-24 2016-06-16 The University Court of the University of Edinburg h Domain 5 of CD163 for Use in Antiviral Compositions Against PRRS, and Transgenic Animals
JP2017502969A (ja) * 2014-01-03 2017-01-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリン調合剤の処方
WO2018167320A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2019143272A1 (en) * 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Fc IgG1 heavy chain constant region, partial [Homo sapiens]", DATABASE GENBANK [ONLINE], vol. AEV43323, JPN7024003625, 25 July 2016 (2016-07-25), ISSN: 0005577191 *
JCI INSIGHT, vol. Vol.3, No.5, e98522, JPN7024003624, 2018, pages 1 - 12, ISSN: 0005577190 *

Also Published As

Publication number Publication date
WO2021052277A1 (zh) 2021-03-25
KR20220066116A (ko) 2022-05-23
JP2025186253A (ja) 2025-12-23
AU2020348436A1 (en) 2022-04-07
CA3157354A1 (en) 2021-03-25
US20230057622A1 (en) 2023-02-23
EP4032901A1 (en) 2022-07-27
EP4032901A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
JP6856716B2 (ja) フォリスタチンポリペプチドによる障害の処置のための方法および組成物
US8158589B2 (en) Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
CN102232084B (zh) 纽兰格林及其用途
CN102883736B (zh) 用于促进血管生成的肽及其用途
JP2002507546A (ja) 角質細胞増殖因子−２の治療的使用
CN102884073B (zh) 用于促进血管生成的肽及其用途
CN112585159B (zh) 神经调节蛋白多肽片段及其用途
JP7825894B2 (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
JP2022547335A (ja) 組換えヒトニューレグリン誘導体及びその使用
JP7499533B2 (ja) 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
HK40081680A (en) Recombinant human neuregulin derivatives and use thereof
CN112500493A (zh) 重组人神经调节蛋白衍生物及其用途
US20090286729A1 (en) Epidermal Growth Factor Receptor Antagonists and Methods of Use
KR102801906B1 (ko) 피브릴린 재조합 단백질을 포함하는 줄기세포의 평활근세포로의 분화 촉진용 조성물
JP2022504217A (ja) 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法
WO2009116529A1 (ja) ポリペプチドおよび当該ポリペプチドを含む医薬組成物
US20240091306A1 (en) Peptides endowed with angiogenic activity
HK1238658A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422